menu search

Australia exports – comb. confidential items excl.some sitc28099&sitc51099

Exports – Comb. Confidential Items Excl.Some Sitc28099&Sitc51099 in Australia decreased to 924 AUD Million in September from 1050 AUD Million in Aug...

November 4, 2023, 3:44 pm

Candel therapeutics presents preclinical data from its enlighten™ discovery platform at sitc

The first experimental agent from the enLIGHTEN™ Discovery Platform is Alpha-201-macro1, an investigational viral immunotherapy designed to activate...

November 4, 2023, 12:00 pm

Sensei biotherapeutics reports favorable clinical data for sns-101 at 2023 sitc annual meeting

– Clinical dose escalation data for SNS-101 monotherapy show well tolerated safety profile, potentially best-in-class pharmacokinetics, and encourag...

November 3, 2023, 8:05 pm

Kineta reports third quarter 2023 financial results and provides corporate update

Announced positive KVA12123 monotherapy safety data from its ongoing phase 1/2 VISTA-101 clinical trial Enrolled the first patient of KVA12123 in comb...

November 3, 2023, 8:01 pm

Will spin-off plans help site centers (sitc) stock trend higher?

SITE Centers (SITC) under Fitch's "Rating Watch Positive" after it announces Convenience assets spin-off along with its Q3 results. A streamlined reta...

November 3, 2023, 1:32 pm

Coherus presents data from next-generation immuno-oncology programs at 38th annual meeting of society for immunotherapy of cancer (sitc)

– Data demonstrate distinct IL-27-mediated expression of genes associated with immune suppression in vitro, supporting ongoing clinical development ...

November 3, 2023, 12:30 pm

Turnstone biologics presents preclinical data highlighting potential for selected tumor-infiltrating lymphocyte (til) therapy in solid tumors at the 2023 society for immunotherapy of cancer (sitc) ann

Presentations showcase Turnstone’s novel Selected TIL programs which are designed to selectively expand the most potent tumor-reactive T cells for t...

November 3, 2023, 10:00 am

Masonic cancer center, university of minnesota to present data in poster presentation human data readout for phase 1 study to evaluate hcw9218 in solid tumors at sitc 38th annual meeting

HCW9218 is the lead product candidate of HCW Biologics Inc. MIRAMAR, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or...

November 1, 2023, 11:30 am

Scancell melanoma trial data chosen for poster presentation at sitc

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) told investors that it has been selected for a poster presentation of data from the first stage of its Pha...

November 1, 2023, 4:16 am

Xilio to host virtual investor conference call and webcast on monday, november 6, 2023 to review progress across pipeline, including phase 1/2 clinical data for xtx202, a tumor-activated, engineered,

WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and devel...

October 31, 2023, 9:15 am

Iovance biotherapeutics to present clinical and pre-clinical data for tumor infiltrating lymphocyte (til) therapies at society for tumor immunotherapy of cancer's (sitc) 38th annual meeting

SAN CARLOS, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, dev...

October 31, 2023, 9:05 am

Site centers corp. (sitc) reports q3 earnings: what key metrics have to say

Although the revenue and EPS for SITE CENTERS CORP. (SITC) give a sense of how its business performed in the quarter ended September 2023, it might be...

October 30, 2023, 9:48 pm

Site centers corp. (sitc) q3 ffo and revenues top estimates

SITE CENTERS CORP. (SITC) came out with quarterly funds from operations (FFO) of $0.33 per share, beating the Zacks Consensus Estimate of $0.28 per sh...

October 30, 2023, 8:18 pm

Carisma to present first results from in vivo car-m collaboration with moderna at sitc 2023

-Late-breaking abstract to be presented on November 3 rd at 11:30 am PT highlighting pre-clinical data with Moderna -Two additional pre-clinical data ...

October 25, 2023, 9:11 am

Sensei biotherapeutics to present initial clinical data from dose escalation trial of sns-101 at 2023 sitc annual meeting

BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discove...

October 25, 2023, 9:05 am

Site centers: holding steady

Strip Center REITs have slightly outperformed the average REIT YTD, despite a challenging year for REITs as a whole. Strip Center REITs benefit from n...

October 22, 2023, 9:00 am

Here's why you should retain site centers (sitc) stock now

A well-located portfolio, focus on essential retail business and capital-recycling moves bode well for SITE Centers (SITC). However, rising e-commerce...

October 5, 2023, 3:47 pm

Io biotech announces three poster presentations at the society for immunotherapy of cancer’s (sitc) 38th annual meeting

NEW YORK, Oct. 03, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...

October 3, 2023, 8:30 pm

23andme announces poster presentations on 23me-00610, an investigational antibody targeting cd200r1, at the society for immunotherapy of cancer’s (sitc) 2023 annual meeting

23andMe to present data on efficacy and safety and dose selection for the ongoing 23ME-00610 Phase 1/2a clinical trial in patients with advanced solid...

September 27, 2023, 8:05 pm

Cellectis to present pre-clinical data on multi-armored allogeneic muc1-car t-cells targeting triple-negative breast cancer at the society for immunotherapy of cancer (sitc) 38th annual meeting

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology com...

September 27, 2023, 4:30 pm


Search within

Pages Search Results: